Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic
pharmaceutical company focused on the discovery, development and
commercialization of first-in-class therapies for the treatment of
patients with open-angle glaucoma, dry eye, retinal diseases and
potentially other diseases of the eye, today announced that Peter
J. McDonnell, M.D., has been appointed to the Company’s Board of
Directors and will also be a member of both the Nominating and
Corporate Governance and Compensation Committees of the Board.
Dr. McDonnell has served as the William Holland Wilmer Professor
of Ophthalmology and Director of the Wilmer Eye Institute at the
Johns Hopkins University School of Medicine, the largest
ophthalmology department in the country, since 2003. A
board-certified ophthalmologist and specialist in corneal disease
and surgery, Dr. McDonnell is an international leader in corneal
transplantation, laser refractive surgery and the treatment of dry
eye. He has published over 250 scientific articles and holds ten
patents. A member of many professional ophthalmology and medical
societies, Dr. McDonnell has been the Chief Medical Editor of
Ophthalmology Times since 2004 and has also served on the editorial
boards of numerous ophthalmology journals. He also serves as the
Immediate Past President and director of the National Alliance for
Eye and Vision Research and the Alliance for Eye and Vision
Research and is Vice President of the Pan-American Ophthalmological
Association, the second largest professional organization of
ophthalmologists in the world.
“We are very pleased to welcome Peter to the Company’s Board. As
a highly respected leader in ophthalmology, his clinical experience
and broad business perspective will be invaluable as we continue to
grow our glaucoma franchise and advance our clinical pipeline,”
said Vicente Anido, Jr., Ph.D., Chairman and Chief Executive
Officer at Aerie.
“I am excited to join Aerie’s board. As a clinician, I have seen
firsthand the positive impact of Rhopressa® and Rocklatan® on
glaucoma patients and look forward to working with the Company’s
Board and management team as Aerie also addresses the unmet needs
in dry eye and retinal disease,” said Peter J. McDonnell, M.D.
About Aerie Pharmaceuticals, Inc.
Aerie is an ophthalmic pharmaceutical company focused on the
discovery, development and commercialization of first-in-class
therapies for the treatment of patients with open-angle glaucoma,
dry eye, retinal diseases and potentially other diseases of the
eye. Aerie’s first product, Rhopressa® (netarsudil ophthalmic
solution) 0.02%, a once-daily eye drop approved by the U.S. Food
and Drug Administration (FDA) for the reduction of elevated
intraocular pressure (IOP) in patients with open-angle glaucoma or
ocular hypertension, was launched in the United States in April
2018. In clinical trials of Rhopressa®, the most common adverse
reactions were conjunctival hyperemia, corneal verticillata,
instillation site pain, and conjunctival hemorrhage. More
information about Rhopressa®, including the product label, is
available at www.rhopressa.com. Aerie’s second product for the
reduction of elevated IOP in patients with open-angle glaucoma or
ocular hypertension, Rocklatan® (netarsudil and latanoprost
ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose
combination of Rhopressa® and the widely-prescribed PGA
(prostaglandin analog) latanoprost, was launched in the United
States in May 2019. In clinical trials of Rocklatan®, the most
common adverse reactions were conjunctival hyperemia, corneal
verticillata, instillation site pain, and conjunctival hemorrhage.
More information about Rocklatan®, including the product label, is
available at www.rocklatan.com. Aerie continues to focus on global
expansion and the development of additional product candidates and
technologies in ophthalmology, including for wet age-related
macular degeneration and diabetic macular edema. More information
is available at www.aeriepharma.com.
Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. We may, in some cases, use terms
such as “predicts,” “believes,” “potential,” “proposed,”
“continue,” “estimates,” “anticipates,” “expects,” “plans,”
“intends,” “may,” “could,” “might,” “will,” “should,” “exploring,”
“pursuing” or other words that convey uncertainty of future events
or outcomes to identify these forward-looking statements.
Forward-looking statements in this release include statements
regarding our intentions, beliefs, projections, outlook, analyses
or current expectations concerning, among other things: the
duration and severity of the coronavirus disease (COVID-19)
outbreak, including the impact on our clinical and commercial
operations, demand for our products and financial results and
condition of our global supply chains; our expectations regarding
the commercialization and manufacturing of Rhopressa®, Rocklatan®,
Rhokiinsa® and Roclanda® or any current or future product
candidates, including the timing, cost or other aspects of their
commercial launch; our commercialization, marketing, manufacturing
and supply management capabilities and strategies in and outside of
the United States; the success, timing and cost of our ongoing and
anticipated preclinical studies and clinical trials for Rhopressa®
and Rocklatan®, with respect to regulatory approval outside of the
United States, and any current or future product candidates,
including statements regarding the timing of initiation and
completion of the studies and trials, such as statements in this
press release regarding any expected clinical trials for AR-15512
(formerly AVX-012), AR-1105 or AR-13503 and the results of such
clinical trials; our expectations regarding the effectiveness of
Rhopressa®, Rocklatan®, Rhokiinsa®, Roclanda® or any current or
future product candidates; the timing of and our ability to
request, obtain and maintain FDA or other regulatory authority
approval of, or other action with respect to, as applicable,
Rhopressa®, Rocklatan® or any current or future product candidates,
including the expected timing of, and timing of regulatory and/or
other review of, filings for, as applicable, Rhopressa®, Rocklatan®
or any current or future product candidates; the potential
advantages of Rhopressa® and Rocklatan® or any current or future
product candidates; our plans to pursue development of additional
product candidates and technologies; our plans to explore possible
uses of our existing proprietary compounds beyond glaucoma,
including development of our retina program; our ability to protect
our proprietary technology and enforce our intellectual property
rights; and our expectations regarding strategic operations,
including our ability to in-license or acquire additional
ophthalmic products, product candidates or technologies. In
particular, FDA approval of Rhopressa® and Rocklatan® and EMA
approval of Rhokiinsa® do not constitute regulatory approval of
Rhopressa® and Rocklatan® in other jurisdictions, including EMA
approval of Roclanda®, and there can be no assurance that we will
receive regulatory approval for Rhopressa® and Rocklatan® in such
other jurisdictions, including EMA approval of Roclanda®. In
addition, FDA approval of Rhopressa® and Rocklatan® do not
constitute FDA approval of our current or any future product
candidates, and there can be no assurance that we will receive FDA
approval for our current or any future product candidates.
Furthermore, EMA acceptance of the MAA for Roclanda® does not
constitute EMA approval of Roclanda®, and there can be no assurance
that we will receive EMA approval of Roclanda®. In addition, the
acceptance of the INDs by the FDA for AR-15512, AR-1105 and
AR-13503 do not constitute FDA approval of AR-15512, AR-1105 or
AR-13503 and the outcomes of later clinical trials for AR-15512,
AR-1105 or AR-13503 may not be sufficient to submit an NDA with the
FDA or to receive FDA approval. By their nature, forward-looking
statements involve risks and uncertainties because they relate to
events, competitive dynamics, industry change and other factors
beyond our control, and depend on regulatory approvals and economic
and other environmental circumstances that may or may not occur in
the future or may occur on longer or shorter timelines than
anticipated. We discuss many of these risks in greater detail under
the heading “Risk Factors” in the quarterly and annual reports that
we file with the Securities and Exchange Commission (SEC).
Forward-looking statements are not guarantees of future performance
and our actual results of operations, financial condition and
liquidity, and the development of the industry in which we operate
may differ materially from the forward-looking statements contained
in this press release. Any forward-looking statements that we make
in this press release speak only as of the date of this press
release. We assume no obligation to update our forward-looking
statements whether as a result of new information, future events or
otherwise, after the date of this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200611005041/en/
Media: Tad Heitmann 949-526-8747; theitmann@aeriepharma.com
Investors: Ami Bavishi 908-947-3949; abavishi@aeriepharma.com
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Apr 2024 to May 2024
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From May 2023 to May 2024